Furthermore, enhanced PEDF anti-metastatic function is associated with post-menopausal oestrogen levels in ER+/HER2- BC and pre-menopausal oestrogen levels in TNBC cells (manuscript submitted). Here, ERBB2 is linked to breast cancer.